Candesartan—the next anti-amyloid drug?

This scientific commentary refers to ‘Safety and biomarker effects of candesartan in non-hypertensive adults with prodromal Alzheimer's disease’ by Hajjar et al. (https://doi.org/10.1093/braincomms/fcac270).

Detalles Bibliográficos
Autor principal: Yasar, Sevil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Scientific Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9683388/
https://www.ncbi.nlm.nih.gov/pubmed/36440098
http://dx.doi.org/10.1093/braincomms/fcac293
_version_ 1784835049762324480
author Yasar, Sevil
author_facet Yasar, Sevil
author_sort Yasar, Sevil
collection PubMed
description This scientific commentary refers to ‘Safety and biomarker effects of candesartan in non-hypertensive adults with prodromal Alzheimer's disease’ by Hajjar et al. (https://doi.org/10.1093/braincomms/fcac270).
format Online
Article
Text
id pubmed-9683388
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-96833882022-11-25 Candesartan—the next anti-amyloid drug? Yasar, Sevil Brain Commun Scientific Commentary This scientific commentary refers to ‘Safety and biomarker effects of candesartan in non-hypertensive adults with prodromal Alzheimer's disease’ by Hajjar et al. (https://doi.org/10.1093/braincomms/fcac270). Oxford University Press 2022-11-07 /pmc/articles/PMC9683388/ /pubmed/36440098 http://dx.doi.org/10.1093/braincomms/fcac293 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the Guarantors of Brain. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Scientific Commentary
Yasar, Sevil
Candesartan—the next anti-amyloid drug?
title Candesartan—the next anti-amyloid drug?
title_full Candesartan—the next anti-amyloid drug?
title_fullStr Candesartan—the next anti-amyloid drug?
title_full_unstemmed Candesartan—the next anti-amyloid drug?
title_short Candesartan—the next anti-amyloid drug?
title_sort candesartan—the next anti-amyloid drug?
topic Scientific Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9683388/
https://www.ncbi.nlm.nih.gov/pubmed/36440098
http://dx.doi.org/10.1093/braincomms/fcac293
work_keys_str_mv AT yasarsevil candesartanthenextantiamyloiddrug

Ejemplares similares